Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma
Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma
复制标题
DOI：
10.1111/liv.12307
复制
发表时间：
2014-04-01
影响因子：
6.7
通讯作者：
Lau, Wan Y.
中科院分区：
文献类型：
--
作者：
Gao Heng-jun;Zhang Yao-jun;Lau, Wan Y.
背景与目的经动脉化疗栓塞术（TACE）被推荐为治疗中间型肝细胞癌（HCC）的标准治疗方法。我们分析了TACE与BCLC B期HBV相关HCC的合理性和有效性在一个大的cohort.MethodsA共1516例BCLC B期HBV相关HCC 7724谁接受TACE作为初始治疗的回顾性研究。根据mRECIST标准评估治疗反应。采用寿命表法计算总生存期，并与Mantel-Cox检验进行比较。采用考克斯比例hazards.Results1，3和5年的总生存率分别为84%，29%和19%，所有患者的预后因素进行了评估。甲胎蛋白、Child-Pugh分级、肿瘤大小和数目是独立的预后因素。CR、PR、SD和PD患者的5年生存率分别为39%、19%、2%和0%（P
Background & AimsTransarterial chemoembolization (TACE) is recommended as standard care for intermediate hepatocellular carcinoma (HCC). We analyse the rationality and effectiveness of TACE with BCLC B stage HBV-related HCC in a large cohort.MethodsA total of 1516 patients with BCLC B stage from 7724 HBV-related HCCs who received TACE as initial treatment were retrospectively studied. The treatment response was assessed by the mRECIST criteria. The overall survival was calculated with life-table method and compared with the Mantel-Cox test. The prognostic factors were assessed using Cox proportional hazards.ResultsThe 1-, 3- and 5-year overall survival rates were 84%, 29% and 19% respectively for all patients. Alpha-foetoprotein, Child-Pugh classification, tumour size and number were independent prognostic factors. The 5-year survival for patients with CR, PR, SD and PD were 39%, 19%, 2% and 0%, respectively (P